Macrolide-Clarithromycin Task-Force for the Treatment and Prophylaxis of Covid-19 as a Single Agent

Autores
Mansilla, Eduardo; Martínez, Ricardo Rangel; Marin, Gustavo Horacio; Filho, Idiberto Zotarelli; Rivas, Elsa; Rivas, Jaime; Carvalho, Katherine Athayde Teixeira de; Dayer, Mohammad Reza; Samadikuchaksaraei, Alí
Año de publicación
2020
Idioma
inglés
Tipo de recurso
artículo
Estado
versión publicada
Descripción
SARS-CoV-2 is a novel RNA coronavirus responsible of a deadly pandemic: the clinical illness COVID-19. With only one authorized drug for emergency use in critically ill patients: Remdesivir, there is not any other approved drug or vaccine yet with proven potential to overcome this infection. We exposed here many scientific evidences to support our novel idea that a macrolide, basically Clarithromycin, could be effective as a single agent for treatment and prophylaxis of COVID-19. Clarithromycin could change the history of this pandemic. It could reduce the costs of treatment and the potential adverse effects when combining more than one drug such as with Hydroxychloroquine. Clarithromycin treatment and prophylaxis as a single agent could be much more simple, safe and cheaper as giving Chloroquine or Hydroxychloroquine alone or in combination with Azithromycin as well as other therapeutic options.
Fil: Mansilla, Eduardo. Universidad Nacional de La Plata. Facultad de Ciencias Médicas; Argentina
Fil: Martínez, Ricardo Rangel. ExomePharma; México
Fil: Marin, Gustavo Horacio. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina. Universidad Nacional de La Plata. Facultad de Ciencias Médicas; Argentina
Fil: Filho, Idiberto Zotarelli. Faceres Medical School; Brasil
Fil: Rivas, Elsa. Hospital de la Amistad Perú - Corea San Rosa II; Perú
Fil: Rivas, Jaime. Hospital de la Amistad Perú - Corea San Rosa II; Perú
Fil: Carvalho, Katherine Athayde Teixeira de. Research Institute Pelé Little Prince; Brasil
Fil: Dayer, Mohammad Reza. Shahid Chamran University of Ahvaz; Irán
Fil: Samadikuchaksaraei, Alí. Iran University of Medical Sciences; Irán
Materia
Antibiotics
COVID-19
Macrolides
Nivel de accesibilidad
acceso abierto
Condiciones de uso
https://creativecommons.org/licenses/by/2.5/ar/
Repositorio
CONICET Digital (CONICET)
Institución
Consejo Nacional de Investigaciones Científicas y Técnicas
OAI Identificador
oai:ri.conicet.gov.ar:11336/108870
Acceder
id CONICETDig_4d0804cbf3fe04efd318ef3115957d23
oai_identifier_str oai:ri.conicet.gov.ar:11336/108870
network_acronym_str CONICETDig
repository_id_str 3498
network_name_str CONICET Digital (CONICET)
spelling Macrolide-Clarithromycin Task-Force for the Treatment and Prophylaxis of Covid-19 as a Single AgentMansilla, EduardoMartínez, Ricardo RangelMarin, Gustavo HoracioFilho, Idiberto ZotarelliRivas, ElsaRivas, JaimeCarvalho, Katherine Athayde Teixeira deDayer, Mohammad RezaSamadikuchaksaraei, AlíAntibioticsCOVID-19Macrolideshttps://purl.org/becyt/ford/3.1https://purl.org/becyt/ford/3SARS-CoV-2 is a novel RNA coronavirus responsible of a deadly pandemic: the clinical illness COVID-19. With only one authorized drug for emergency use in critically ill patients: Remdesivir, there is not any other approved drug or vaccine yet with proven potential to overcome this infection. We exposed here many scientific evidences to support our novel idea that a macrolide, basically Clarithromycin, could be effective as a single agent for treatment and prophylaxis of COVID-19. Clarithromycin could change the history of this pandemic. It could reduce the costs of treatment and the potential adverse effects when combining more than one drug such as with Hydroxychloroquine. Clarithromycin treatment and prophylaxis as a single agent could be much more simple, safe and cheaper as giving Chloroquine or Hydroxychloroquine alone or in combination with Azithromycin as well as other therapeutic options.Fil: Mansilla, Eduardo. Universidad Nacional de La Plata. Facultad de Ciencias Médicas; ArgentinaFil: Martínez, Ricardo Rangel. ExomePharma; MéxicoFil: Marin, Gustavo Horacio. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina. Universidad Nacional de La Plata. Facultad de Ciencias Médicas; ArgentinaFil: Filho, Idiberto Zotarelli. Faceres Medical School; BrasilFil: Rivas, Elsa. Hospital de la Amistad Perú - Corea San Rosa II; PerúFil: Rivas, Jaime. Hospital de la Amistad Perú - Corea San Rosa II; PerúFil: Carvalho, Katherine Athayde Teixeira de. Research Institute Pelé Little Prince; BrasilFil: Dayer, Mohammad Reza. Shahid Chamran University of Ahvaz; IránFil: Samadikuchaksaraei, Alí. Iran University of Medical Sciences; IránScientific Research2020-06info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionhttp://purl.org/coar/resource_type/c_6501info:ar-repo/semantics/articuloapplication/pdfapplication/pdfhttp://hdl.handle.net/11336/108870Mansilla, Eduardo; Martínez, Ricardo Rangel; Marin, Gustavo Horacio; Filho, Idiberto Zotarelli; Rivas, Elsa; et al.; Macrolide-Clarithromycin Task-Force for the Treatment and Prophylaxis of Covid-19 as a Single Agent; Scientific Research; Pharmacology & Pharmacy; 11; 6; 6-2020; 85-1042157-9423CONICET DigitalCONICETenginfo:eu-repo/semantics/altIdentifier/doi/10.4236/pp.2020.116009info:eu-repo/semantics/altIdentifier/url/https://www.scirp.org/journal/paperinformation.aspx?paperid=100971info:eu-repo/semantics/openAccesshttps://creativecommons.org/licenses/by/2.5/ar/reponame:CONICET Digital (CONICET)instname:Consejo Nacional de Investigaciones Científicas y Técnicas2025-10-15T14:40:23Zoai:ri.conicet.gov.ar:11336/108870instacron:CONICETInstitucionalhttp://ri.conicet.gov.ar/Organismo científico-tecnológicoNo correspondehttp://ri.conicet.gov.ar/oai/requestdasensio@conicet.gov.ar; lcarlino@conicet.gov.arArgentinaNo correspondeNo correspondeNo correspondeopendoar:34982025-10-15 14:40:24.06CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicasfalse
dc.title.none.fl_str_mv Macrolide-Clarithromycin Task-Force for the Treatment and Prophylaxis of Covid-19 as a Single Agent
title Macrolide-Clarithromycin Task-Force for the Treatment and Prophylaxis of Covid-19 as a Single Agent
spellingShingle Macrolide-Clarithromycin Task-Force for the Treatment and Prophylaxis of Covid-19 as a Single Agent
Mansilla, Eduardo
Antibiotics
COVID-19
Macrolides
title_short Macrolide-Clarithromycin Task-Force for the Treatment and Prophylaxis of Covid-19 as a Single Agent
title_full Macrolide-Clarithromycin Task-Force for the Treatment and Prophylaxis of Covid-19 as a Single Agent
title_fullStr Macrolide-Clarithromycin Task-Force for the Treatment and Prophylaxis of Covid-19 as a Single Agent
title_full_unstemmed Macrolide-Clarithromycin Task-Force for the Treatment and Prophylaxis of Covid-19 as a Single Agent
title_sort Macrolide-Clarithromycin Task-Force for the Treatment and Prophylaxis of Covid-19 as a Single Agent
dc.creator.none.fl_str_mv Mansilla, Eduardo
Martínez, Ricardo Rangel
Marin, Gustavo Horacio
Filho, Idiberto Zotarelli
Rivas, Elsa
Rivas, Jaime
Carvalho, Katherine Athayde Teixeira de
Dayer, Mohammad Reza
Samadikuchaksaraei, Alí
author Mansilla, Eduardo
author_facet Mansilla, Eduardo
Martínez, Ricardo Rangel
Marin, Gustavo Horacio
Filho, Idiberto Zotarelli
Rivas, Elsa
Rivas, Jaime
Carvalho, Katherine Athayde Teixeira de
Dayer, Mohammad Reza
Samadikuchaksaraei, Alí
author_role author
author2 Martínez, Ricardo Rangel
Marin, Gustavo Horacio
Filho, Idiberto Zotarelli
Rivas, Elsa
Rivas, Jaime
Carvalho, Katherine Athayde Teixeira de
Dayer, Mohammad Reza
Samadikuchaksaraei, Alí
author2_role author
author
author
author
author
author
author
author
dc.subject.none.fl_str_mv Antibiotics
COVID-19
Macrolides
topic Antibiotics
COVID-19
Macrolides
purl_subject.fl_str_mv https://purl.org/becyt/ford/3.1
https://purl.org/becyt/ford/3
dc.description.none.fl_txt_mv SARS-CoV-2 is a novel RNA coronavirus responsible of a deadly pandemic: the clinical illness COVID-19. With only one authorized drug for emergency use in critically ill patients: Remdesivir, there is not any other approved drug or vaccine yet with proven potential to overcome this infection. We exposed here many scientific evidences to support our novel idea that a macrolide, basically Clarithromycin, could be effective as a single agent for treatment and prophylaxis of COVID-19. Clarithromycin could change the history of this pandemic. It could reduce the costs of treatment and the potential adverse effects when combining more than one drug such as with Hydroxychloroquine. Clarithromycin treatment and prophylaxis as a single agent could be much more simple, safe and cheaper as giving Chloroquine or Hydroxychloroquine alone or in combination with Azithromycin as well as other therapeutic options.
Fil: Mansilla, Eduardo. Universidad Nacional de La Plata. Facultad de Ciencias Médicas; Argentina
Fil: Martínez, Ricardo Rangel. ExomePharma; México
Fil: Marin, Gustavo Horacio. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina. Universidad Nacional de La Plata. Facultad de Ciencias Médicas; Argentina
Fil: Filho, Idiberto Zotarelli. Faceres Medical School; Brasil
Fil: Rivas, Elsa. Hospital de la Amistad Perú - Corea San Rosa II; Perú
Fil: Rivas, Jaime. Hospital de la Amistad Perú - Corea San Rosa II; Perú
Fil: Carvalho, Katherine Athayde Teixeira de. Research Institute Pelé Little Prince; Brasil
Fil: Dayer, Mohammad Reza. Shahid Chamran University of Ahvaz; Irán
Fil: Samadikuchaksaraei, Alí. Iran University of Medical Sciences; Irán
description SARS-CoV-2 is a novel RNA coronavirus responsible of a deadly pandemic: the clinical illness COVID-19. With only one authorized drug for emergency use in critically ill patients: Remdesivir, there is not any other approved drug or vaccine yet with proven potential to overcome this infection. We exposed here many scientific evidences to support our novel idea that a macrolide, basically Clarithromycin, could be effective as a single agent for treatment and prophylaxis of COVID-19. Clarithromycin could change the history of this pandemic. It could reduce the costs of treatment and the potential adverse effects when combining more than one drug such as with Hydroxychloroquine. Clarithromycin treatment and prophylaxis as a single agent could be much more simple, safe and cheaper as giving Chloroquine or Hydroxychloroquine alone or in combination with Azithromycin as well as other therapeutic options.
publishDate 2020
dc.date.none.fl_str_mv 2020-06
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
http://purl.org/coar/resource_type/c_6501
info:ar-repo/semantics/articulo
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv http://hdl.handle.net/11336/108870
Mansilla, Eduardo; Martínez, Ricardo Rangel; Marin, Gustavo Horacio; Filho, Idiberto Zotarelli; Rivas, Elsa; et al.; Macrolide-Clarithromycin Task-Force for the Treatment and Prophylaxis of Covid-19 as a Single Agent; Scientific Research; Pharmacology & Pharmacy; 11; 6; 6-2020; 85-104
2157-9423
CONICET Digital
CONICET
url http://hdl.handle.net/11336/108870
identifier_str_mv Mansilla, Eduardo; Martínez, Ricardo Rangel; Marin, Gustavo Horacio; Filho, Idiberto Zotarelli; Rivas, Elsa; et al.; Macrolide-Clarithromycin Task-Force for the Treatment and Prophylaxis of Covid-19 as a Single Agent; Scientific Research; Pharmacology & Pharmacy; 11; 6; 6-2020; 85-104
2157-9423
CONICET Digital
CONICET
dc.language.none.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv info:eu-repo/semantics/altIdentifier/doi/10.4236/pp.2020.116009
info:eu-repo/semantics/altIdentifier/url/https://www.scirp.org/journal/paperinformation.aspx?paperid=100971
dc.rights.none.fl_str_mv info:eu-repo/semantics/openAccess
https://creativecommons.org/licenses/by/2.5/ar/
eu_rights_str_mv openAccess
rights_invalid_str_mv https://creativecommons.org/licenses/by/2.5/ar/
dc.format.none.fl_str_mv application/pdf
application/pdf
dc.publisher.none.fl_str_mv Scientific Research
publisher.none.fl_str_mv Scientific Research
dc.source.none.fl_str_mv reponame:CONICET Digital (CONICET)
instname:Consejo Nacional de Investigaciones Científicas y Técnicas
reponame_str CONICET Digital (CONICET)
collection CONICET Digital (CONICET)
instname_str Consejo Nacional de Investigaciones Científicas y Técnicas
repository.name.fl_str_mv CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicas
repository.mail.fl_str_mv dasensio@conicet.gov.ar; lcarlino@conicet.gov.ar
_version_ 1846082895673819136
score 13.22299

Publicaciones similares